|Bid||3.00 x 300|
|Ask||4.75 x 100|
|Day's Range||4.12 - 4.26|
|52 Week Range||3.20 - 15.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.50|
NEW YORK, Feb. 06, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the ...
NEW YORK, Jan. 03, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that President and Chief Executive Officer James F. Oliviero will present a company overview at Biotech ...
NEW YORK, Dec. 14, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci ...
Checkpoint Therapeutics Inc (NASDAQ: CKPT ), a nano-cap therapeutics company that focuses on developing anti-cancer agents , has lost more than half of its value over the past few months but some analysts ...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) boasts an impressive portfolio of immuno-oncology and anti-cancer agents that have the potential for approvals as both mono- and combination therapies. ...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) announces the dosing of its first patient in a Phase I trial for CK-301, which we discuss in a prior article . CK-301 is a fully human monoclonal IgG1 ...
NASDAQ:CKPT Checkpoint Therapeutics Inc. (NASDAQ:CKPT) holds a portfolio of targeted anti-cancer and immuno-oncology agents which it is developing for both mono- and combination therapies in solid tumors. ...
Checkpoint Therapeutics, Inc. (CKPT) is a majority-controlled subsidiary of Fortress Biotech (FBIO) focused on developing a portfolio of immune-enhanced combination cancer therapies in solid tumors. Checkpoint’s strategy is to acquire, develop and commercialize immuno-oncology and targeted anti-cancer medicines by acquiring rights or ownership in promising molecules, then funding their research and development to bring the technologies to market. The company’s portfolio currently consists of six drug candidates in preclinical and Phase I clinical trials. Two of the compounds are immuno-oncology agents and four are targeted anti-cancer agents. Checkpoint plans to develop its drug candidates both as monotherapies, and then in combination with each other. Importantly, owning all components of a combination therapy should provide Checkpoint with pricing leverage versus competitors upon commercialization.